TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Intravenous Nutrition Development, Research Organization (INDRO) AB
Closing information (x1000 SEK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
300
|
237
|
165 |
| Financial expenses |
0
|
3
|
0 |
| Earnings before taxes |
426
|
1
|
1 |
| EBITDA |
-125
|
3
|
1 |
| Total assets |
5,053
|
4,543
|
4,494 |
| Current assets |
616
|
106
|
57 |
| Current liabilities |
209
|
124
|
76 |
| Equity capital |
4,844
|
4,419
|
4,418 |
| - share capital |
200
|
200
|
200 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
95.9%
|
97.3%
|
98.3% |
| Turnover per employee |
300
|
237
|
165 |
| Profit as a percentage of turnover |
142.0%
|
0.4%
|
0.6% |
| Return on assets (ROA) |
8.4%
|
0.1%
|
0.0% |
| Current ratio |
294.7%
|
85.5%
|
75.0% |
| Return on equity (ROE) |
8.8%
|
0.0%
|
0.0% |
| Change turnover |
63
|
72
|
43 |
| Change turnover % |
27%
|
44%
|
35% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.